Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18545631 | 1.00 | GAA (0.58) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19184734 | 0.75 | GAA (0.54) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL19186311 | 0.75 | GAA (0.43) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1814713 | 0.74 | GAA (1.00) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL13060033 | 0.73 | GAA (0.52) | GAAL3MBTL1 | |
| SCHEMBL24406828 | 0.72 | GAA (0.41) | GAAL3MBTL1 | |
| SCHEMBL879602 | 0.72 | GAA (0.50) | GAAL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL377190 | 0.72 | GAA (0.56) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL18545708 | 0.72 | GAA (0.56) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL16245365 | 0.72 | GAA (0.56) | GAAL3MBTL1ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2702400-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | Children's Hospital & Research Center at Oakland (US) | 2014-03-05 | — | — | EP | claimed |
| WO-2012149473-A2 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2012-11-01 | — | — | WO | claimed |
| US-20230357558-A1 | RESIN COMPOSITION, PREPREG USING SAME, FILM PROVIDED WITH RESIN, METAL FOIL PROVIDED WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230040736-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-02-09 | — | — | US | disclosed |
| WO-2022128859-A1 | NEW ELECTRODE MATERIAL FOR PRINTING POLYMER BATTERIES | EVONIK OPERATIONS GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| EP-2984084-B1 | HIGHLY EFFICIENT POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION | BRUKER FRANCE S A S (FR) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022059625-A1 | RESIN COMPOSITION, PREPREG USING SAME, FILM PROVIDED WITH RESIN, METAL FOIL PROVIDED WITH RESIN, METAL-CLAD LAMINATE, AND WIRING BOARD | パナソニックＩＰマネジメント株式会社 | 2022-03-24 | — | — | WO | disclosed |
| WO-2021028171-A1 | THIRD GENERATION DENDRIMER, PROCESS FOR PRODUCTION THEREOF AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2021-02-18 | — | — | WO | disclosed |
| WO-2019007989-A9 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-12-26 | — | — | WO | disclosed |
| US-20190345293-A1 | COPOLYMER CONTAINING CYCLIC NITROXIDE RADICAL AND TRIALKOXYSILYL IN SIDE CHAIN, AND USE THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2019-11-14 | — | — | US | disclosed |
| EP-3202803-B1 | POLY(ETHYLENE GLYCOL)-B-POLY(HALOMETHYLSTYRENE) AND DERIVATIVES THEREOF, AND PRODUCTION PROCESS THEREFOR | UNIV TSUKUBA (JP) | 2019-09-18 | — | — | EP | disclosed |
| WO-2008109740-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008008437-A1 | POLY(ESTER-AMIDE)S, DERIVATIVES THEREOF, AND THEIR USE WITH IMPLANTABLE MEDICAL DEVICES | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070231744-A1 | Holographic recording medium | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1186588-A1 | 6-HYDROXY-2-NAPHTHYLCARBINOL AND PROCESS FOR THE PREPARATION THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-4863717-A | Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | GAA 1386/4885L3MBTL1 1225/4885ALDH1A1 92/4885 |
| US-20190345293-A1 | COPOLYMER CONTAINING CYCLIC NITROXIDE RADICAL AND TRIALKOXYSILYL IN SIDE CHAIN, AND USE THEREOF | NOXO1, PPOX, CYBB | GAA 2186/4885L3MBTL1 1540/4885ALDH1A1 2957/4885 |
| US-20230040736-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | NDC1, NUCB2, MDM4 | GAA 2894/4885L3MBTL1 1320/4885ALDH1A1 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.